Bristol-Myers Squibb (NYSE:BMY) and Nordic Bioscience, a Danish company specializing in biomarker technologies, announce a collaboration agreement to develop biomarker technology for the diagnosis and monitoring of fibrotic diseases including non-alcoholic steatohepatitis (NASH).
Under the terms of the agreement, the companies will collaborate on the development of translational biomarkers and diagnostics of NASH in preclinical models of fibrotic diseases and in clinical settings. Financial terms are not disclosed.
Now read: Bristol-Myers: Buyout Bound? »